Dr. Nanda serves as chief development officer for Loxo Oncolog. She has had increasing roles of responsibility in both clinical and pre-clinical development. Most recently Dr. Nanda worked on the clinical development of carfilzomib (Kyprolis) and the approval of omacetaxine (Synribo). Her career in drug development has included roles at Onyx, ChemGenex, Portola, Millennium and Cor.

Dr. Nanda has a BSc Hons in biochemistry and molecular genetics from the University of New South Wales (UNSW), Sydney, Australia, and a Ph.D. in biochemistry and molecular genetics from UNSW and the Victor Chang Cardiac Research Institute, Sydney, Australia.